Fluorescent PARP Inhibitors Applied to Intracranial Glioblastoma: Accumulation and Persistence in Vivo

Rucaparib-containing fluorescent probes (1-3) inhibit PARP1 in cell models. One of these (1) was tested in a murine model and shown to permeate into implanted intracranial glioblastoma tumors and persist there for at least 24 h.